You are here

Immunity Pharma Ltd. (IPL)

Immunity Pharma Ltd. (IPL) uses novel immune-based approaches, employing "switch peptides", to develop therapies for neuro-degenerative diseases. IPL’s drugs are peptides with biologic activity that augments natural self-repair processes utilized by the immune system itself. In particular, it is developing an innovative peptide-based strong anti-apoptotic drug invented by Prof. Irun R. Cohen of the Department of Immunology at The Weizmann Institute of Science, for the treatment of ALS. 

For further information please visit www.immunitypharma.com contact Eran Ovadiaeran@immunitypharma.com or call +972 54 7594059